Gemmer Asset Management LLC Vertex Pharmaceuticals Inc Transaction History

Gemmer Asset Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 22, 2022	SELL	$234.96 - $292.55 $37,358 - $46,515	-159 Closed	0 $0
Q3 2021 Oct 19, 2021	SELL	$181.39 - $202.99 $2,539 - $2,841	-14 Reduced 8.09%	159 $29,000
Q2 2021 Jul 23, 2021	BUY	$187.49 - $221.1 $562 - $663	3 Added 1.76%	173 $35,000
Q1 2021 Apr 20, 2021	BUY	$207.02 - $241.31 $3,105 - $3,619	15 Added 9.68%	170 $37,000
Q4 2020 Jan 28, 2021	SELL	$207.01 - $276.09 $1,449 - $1,932	-7 Reduced 4.32%	155 $37,000

Q2 2020 Jul 31, 2020	BUY	$225.48 - $295.8 $1,578 - $2,070	7 Added 4.52%	162 $47,000
Q4 2019 Jan 17, 2020	SELL	$166.71 - $223.91 $3,834 - $5,149	-23 Reduced 12.92%	155 $34,000
Q3 2019 Oct 11, 2019	BUY	$166.23 - $187.09 $664 - $748	4 Added 2.3%	178 $30,000
Q2 2019 Jul 18, 2019	SELL	$164.61 - $190.37 $12,181 - $14,087	-74 Reduced 29.84%	174 $32,000
Q1 2019 Apr 17, 2019	SELL	$163.73 - $194.7 $2,455 - $2,920	-15 Reduced 5.7%	248 $46,000
Q3 2018 Oct 12, 2018	SELL	$167.73 - $192.74 $13,418 - $15,419	-80 Reduced 23.32%	263 $51,000
Q3 2017 Oct 12, 2017	BUY	$148.13 - $162.24 $50,808 - $55,648	343	343 $52,000

1,637

222M

1.35M

1.49M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $126B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Gemmer Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Gemmer Asset Management LLC with notifications on news.